Oral Tablet Formulations with Lactoferrin, a Cohesive Biomacromolecule.

IF 5.5 3区 医学 Q1 PHARMACOLOGY & PHARMACY
True L Rogers, Andrew J Horton, Thomas Watson, Stephanie Robart, Brooklynn DeFrancesco, Hannah Bishop, Elizabeth Tocce
{"title":"Oral Tablet Formulations with Lactoferrin, a Cohesive Biomacromolecule.","authors":"True L Rogers, Andrew J Horton, Thomas Watson, Stephanie Robart, Brooklynn DeFrancesco, Hannah Bishop, Elizabeth Tocce","doi":"10.3390/pharmaceutics17091151","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background/Objectives:</b> The aim of our research was to understand how excipients, unit operations, and process parameters impact processability and resulting properties, performance, and stability of tablets containing bovine lactoferrin, a cohesive biomacromolecule. <b>Methods:</b> Microcrystalline cellulose (MCC), croscarmellose (xCMC), lactose (LAC), hydroxypropyl methylcellulose (HPMC), and sodium stearyl fumarate (SSF) were used to produce various tablet formulations containing lactoferrin across a concentration range of 5 to 45%, targeting immediate- or controlled release performance. Tablets were made either by direct compression or via dry granulation followed by tableting. In addition to release performance, tablet attributes were characterized for tensile strength, friability, weight uniformity, and content uniformity. <b>Results:</b> Acceptable tablet tensile strength, friability, and performance were obtained for lactoferrin concentrations ranging from 15 to 45%, using a variety of excipients and manufacturing approaches. In several cases, dry granulation improved content uniformity. Excipient choice and tablet compression force impacted drug release, particularly when MCC alone was used as dry binder for immediate release. Dry granulation impacted tablet tensile properties, but did not significantly impact release performance. Lactoferrin-excipient compatibility was demonstrated for up to 2 years in ambient laboratory conditions. <b>Conclusions:</b> The study demonstrates that robust tablets can be produced using excipients and processes amenable to scale-up for industrial production. Consistent, stable, and suitably performing tablets were successfully produced using a variety of excipients, processing approaches, and across a broad concentration range with this cohesive biomacromolecule active pharmaceutical ingredient (API). Both immediate- and controlled release performance modes were possible.</p>","PeriodicalId":19894,"journal":{"name":"Pharmaceutics","volume":"17 9","pages":""},"PeriodicalIF":5.5000,"publicationDate":"2025-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12473581/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmaceutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/pharmaceutics17091151","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Background/Objectives: The aim of our research was to understand how excipients, unit operations, and process parameters impact processability and resulting properties, performance, and stability of tablets containing bovine lactoferrin, a cohesive biomacromolecule. Methods: Microcrystalline cellulose (MCC), croscarmellose (xCMC), lactose (LAC), hydroxypropyl methylcellulose (HPMC), and sodium stearyl fumarate (SSF) were used to produce various tablet formulations containing lactoferrin across a concentration range of 5 to 45%, targeting immediate- or controlled release performance. Tablets were made either by direct compression or via dry granulation followed by tableting. In addition to release performance, tablet attributes were characterized for tensile strength, friability, weight uniformity, and content uniformity. Results: Acceptable tablet tensile strength, friability, and performance were obtained for lactoferrin concentrations ranging from 15 to 45%, using a variety of excipients and manufacturing approaches. In several cases, dry granulation improved content uniformity. Excipient choice and tablet compression force impacted drug release, particularly when MCC alone was used as dry binder for immediate release. Dry granulation impacted tablet tensile properties, but did not significantly impact release performance. Lactoferrin-excipient compatibility was demonstrated for up to 2 years in ambient laboratory conditions. Conclusions: The study demonstrates that robust tablets can be produced using excipients and processes amenable to scale-up for industrial production. Consistent, stable, and suitably performing tablets were successfully produced using a variety of excipients, processing approaches, and across a broad concentration range with this cohesive biomacromolecule active pharmaceutical ingredient (API). Both immediate- and controlled release performance modes were possible.

含乳铁蛋白的口服片剂,一种具有凝聚力的生物大分子。
背景/目的:我们研究的目的是了解辅料、单元操作和工艺参数如何影响含有牛乳铁蛋白(一种内聚生物大分子)的片剂的可加工性和最终的性质、性能和稳定性。方法:以微晶纤维素(MCC)、交联纤维素(xCMC)、乳糖(LAC)、羟丙基甲基纤维素(HPMC)、富马酸硬脂酰钠(SSF)为原料,制备含乳铁蛋白的片剂,其浓度范围为5% ~ 45%,以速释或控释为目标。片剂是通过直接压缩或干燥造粒后压片制成的。除释放性能外,还对片剂的抗拉强度、脆性、重量均匀性和含量均匀性进行了表征。结果:在乳铁蛋白浓度为15% - 45%的范围内,使用多种辅料和生产方法,获得了可接受的片剂抗拉强度、脆性和性能。在一些情况下,干造粒改善了含量均匀性。辅料选择和片剂压缩力影响药物释放,特别是当单用MCC作为立即释放的干粘合剂时。干造粒对片剂的拉伸性能有影响,但对释放性能无显著影响。乳铁蛋白-赋形剂的相容性在环境实验室条件下被证明长达2年。结论:该研究表明,坚固片剂可以生产辅料和工艺适用于工业生产的规模。使用多种赋形剂、加工方法和广泛的浓度范围成功地生产了一致、稳定和性能合适的片剂,其中含有这种内聚的生物大分子活性药物成分(API)。即时和控制释放性能模式都是可能的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Pharmaceutics
Pharmaceutics Pharmacology, Toxicology and Pharmaceutics-Pharmaceutical Science
CiteScore
7.90
自引率
11.10%
发文量
2379
审稿时长
16.41 days
期刊介绍: Pharmaceutics (ISSN 1999-4923) is an open access journal which provides an advanced forum for the science and technology of pharmaceutics and biopharmaceutics. It publishes reviews, regular research papers, communications,  and short notes. Covered topics include pharmacokinetics, toxicokinetics, pharmacodynamics, pharmacogenetics and pharmacogenomics, and pharmaceutical formulation. Our aim is to encourage scientists to publish their experimental and theoretical details in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信